Bridgeway Capital Management
MBX icon

Bridgeway Capital Management’s MBX Biosciences MBX Stock Holding History

Bridgeway Capital Management’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,500
Closed -$224K – 1323
2026
Q1 		$224K Sell
7,500
-2,500
-25% -$85K ﹤0.01% 1010
2025
Q4 		$315K Sell
10,000
-4,200
-30% -$102K 0.01% 921
2025
Q3 		$248K Sell
14,200
-15,000
-51% -$201K 0.01% 972
2025
Q2 		$333K Buy
+29,200
New +$297K 0.01% 846

Other funds holding MBX

Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NEA Management Company
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NVP Associates
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Polar Capital Holdings
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Bridgeway Capital Management's MBX Position: Q2 2026 in Review

Bridgeway Capital Management sold out of MBX Biosciences (MBX) in Q2 2026, closing a stake of 7,500 shares — an estimated $224K sold.

Bridgeway Capital Management first reported a position in MBX in Q2 2025 and held it in 4 quarters. The position peaked at $333K in Q2 2025. 172 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • Bridgeway Capital Management reported no remaining MBX Biosciences position as of Q2 2026 after selling out during the quarter.
  • Bridgeway Capital Management sold 7,500 MBX Biosciences shares in Q2 2026, an estimated $224K.
  • Bridgeway Capital Management first reported a position in MBX Biosciences in Q2 2025 and held it in 4 quarters.
  • Bridgeway Capital Management's MBX Biosciences position peaked at $333K in Q2 2025.
  • 172 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.